Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

· Issued by Vertex Pharmaceuticals Incorporated

On 6ix: 6ix.com/news/vertex-presents-positive-vx-880-results-from-ongoing-phase-1-2-study-in-type-1

Watch Vertex Pharmaceuticals' latest callVertex Pharmaceuticals (NASDAQ:VRTX) Q2 2026 Earnings Call · Replay · Aug 3Read the transcript of Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2026 Earnings Call
Vertex Pharmaceuticals' next earnings callVertex Pharmaceuticals (NASDAQ:VRTX) Q3 2026 Earnings Call · Nov 2, 2026 at 4:30 PM ESTRegister

– All six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide) and had improved glycemic control while reducing or eliminating insulin use –

– The two patients with at least one year of follow-up met the criteria for the primary endpoint of elimination of severe hypoglycemic events (SHEs) and HbA1c

Vertex Pharmaceuticals Incorporated on 6ix

Story so far

Earlier from Vertex Pharmaceuticals

Later from Vertex Pharmaceuticals

All Vertex Pharmaceuticals news releases